Global Herpes Zoster Infection Treatment Market - 2023-2030

Market Overview

Global Herpes Zoster infection treatment market reached US$ 251.2 million in 2022 and is expected to reach US$ 331.0 million by 2030, growing with a CAGR of 3.6% during the forecast period 2023-2030.

Ramsay Hunt Syndrome, also known as herpes zoster oticus, is a shingles-related disorder in which the facial nerve around one of the ears is involved. This is a neurological disorder that is induced by the varicella-zoster virus. The virus is identical to the one that provokes chicken pox and shingles. The condition affects both males and females equally. It induces facial paralysis, resulting in distress, blisters, and hives on one side of the face.

This condition impacts individuals of all generations, but it is additionally familiar in the elderly. Further, presenting manifestations include discomfort, hives, facial paralysis, dysgeusia, hearing failure, tinnitus, dizziness, hoarseness, dysarthria, and others, short-term intricacies of Ramsay Hunt Syndrome include corneal graze and exposure keratopathy, depression, and social nervousness, and transmission of chickenpox to unimmunized or immunocompromised immediate connections.

While long-term flaccid paralysis is improbable, the consequence of synkinesis is very typical. Other long-term intricacies enclose postherpetic neuralgia, scarring from the vesicles, and continuous despair and/or social anxiety due to failure of facial function. The increasing research activities, awareness and support initiatives for such rare disorders among other factors are expected to boost the global market growth during the forecast period.

Market Dynamics

Increasing Number of Research Studies

The Increasing Research Studies are expected to boost the global market growth during the forecast period. For instance, the Solve M.E. funds investigation into the underlying reasons for ME/CFS and Long Covid via the Ramsay Research Grant Program, an unrestricted, peer-reviewed competition for subsidies to fund pilot investigations and data research. The Ramsay Program has been booming in drawing new researchers to the domain of ME/CFS, delivering much-required grants for investigators to engage with the science of the condition and produce pilot data.

For instance, since 2016, 34 investigations have been funded by Ramsay Grants. There is a network of more than 91 investigation collaborators who have been interested in the Ramsay Program. More than 50% of the chief researchers on these projects applied their expertise to investigate ME/CFS for the foremost time and 17 of the projects interested early-career phase investigators. The NINDS sponsors an investigation on shingles and shingles-related disorders. Recent investigations concentrate on the association between the perseverance of neurotropic viruses and the growth of neurological conditions enclosing herpes simplex and varicella-zoster viruses. Hence, with the help of these studies, researchers are finding novel treatment methodolgies to treat this rare disease which is enhanceing the market growth.

Increasing Initiatives for Rare Disease

The increasing initiatives to fight against rare disorders are also contributing to the global market growth during the forecast period. For instance, in May 2023, Takeda Biopharmaceuticals India Private Limited (previously comprehended as Baxalta Bioscience India Private Limited), a multinational values-based, R & D-driven biopharmaceutical top corporation led the dissemination of its general health initiatives in supporting the health system for rare diseases (RD) in India.

Moreover, in July 2023, the FDA started receiving submissions from enterprises and stakeholders to partake in a unique pilot program sustaining the growth of unexplored FDA-grade effectiveness endpoints to treat rare disorders. The Rare Disease Endpoint Advancement (RDEA) Pilot Program was launched in October 2022 as a collaborative endeavor between the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).

Frequent Misdiagnosis of the Condition

The difficulty in diagnosis of the Ramsy Hunt Syndrome is expected to hamper the global market growth during the forecast period. As the manifestations of Ramsay Hunt Syndrome differ from individual to individual. Affected people generally encounter paralysis of the facial nerve and a rash impacting the ear. These two manifestations do not consistently appear at the identical moment. In the majority of individuals, solely one side of the face is impacted.

Diagnosis is established on a comprehensive clinical evaluation, exhaustive patient record, and identification of typical manifestations (i.e., one-sided facial palsy and/or a rash around the ear). A representative from the fluid-filled blistering rash encircling the ear can be utilized to establish the diagnosis. These hives are a valid indicator that the condition is Ramsay Hunt Syndrome and not Bell's palsy, acoustic neuroma, or trigeminal neuralgia. In a survey of 206 RHS patients in the UK, Facial Palsy UK encountered that above 50% of those with RHS had been originally misdiagnosed as retaining Bell's palsy.

Low Prevalence of the Condition Globally

The low global prevalence and detection of Herpes Zoster Oticus or Ramsy Hunt Syndrome is another factor that is expected to slow the global herpes zoster infection treatment market growth during the forecast period. For instance, in less than 1% of zoster patients involve the facial nerve and develop Ramsay Hunt Syndrome. RHS is an extremely rare viral disorder that is associated with chickenpox and the shingles virus that leads to facial weakness or paralysis.

Ramsay Hunt Syndrome is believed to be the reason behind only 20% of clinically analyzed patients diagnosed with Bell palsy. Additionally, the spontaneous remission of the facial palsy induced by VZV appears only in a small number of cases, without the appropriate treatment, just 20% reach full recovery. Further, the lack of awareness leads to low rate of diagnosis which again add-up to the low prevalence of the condition globally.

Segment Analysis

The Global Herpes Zoster Infection Treatment Market is segmented based on treatment type, route of administration, distribution channel and region.

Antiviral Drugs to Dominate the Market

Antiviral therapy is solely efficacious against virus reproduction in herpes zoster infections that is, it can contain additional multiplication and spread of the varicella-zoster virus but cannot eliminate the viruses. Oral antiviral therapy has been considered in the therapy of herpes zoster infections in other parts of the body and has been ascertained by studies to reduce the stringency of herpes zoster infection in immunocompromised adults.

Further, it lowers the period of viral shedding and new lesion appearance, thereby increasing the rash healing rate and lessening the duration of pain and thus are considered to be the first line of treatment against Ramsay Hunt Syndrome. The most typically prescribed antivirals for Ramsay Hunt Syndrome include Zovirax, Famvir, and Valtrex. Antiviral medications have been comprehended to induce side effects like headaches and dizziness.

Geographical Penetration

Increasing Number of Herpes Zoster Cases in North America dominates the region

With the increasing cases of Ramsay Hunt Syndrome in North America and the presence of the most advanced healthcare infrastructure North America is expected to hold around 43.2% most of the global market share throughout the forecast period. For instance, according to the National Organization for Rare Disorders, Ramsay Hunt Syndrome impacts approximately 5 out of every 100,000 individuals annually in the U.S. Nevertheless, most researchers believe the disorder is periodically undiagnosed or misdiagnosed. This creates difficulty to determine its frequency.

The condition is among the second most highly typical reason for facial nerve paralysis, making up for over 7% of all patients. Ramsay Hunt Syndrome transpires when the varicella-zoster virus reactivates in the facial nerve, which is the cranial nerve that involves the face, tongue, and inner ear. Therefore, the growing cases of the varicella-zoster virus demonstrate the expanded preponderance of the infection in this region. For instance, according to the CDC, roughly one out of three individuals in the United States are expected to develop herpes zoster during their lifetime. Many individuals have only one attack, nonetheless, herpes zoster can recur.

COVID-19 Impact Analysis

Varicella-zoster virus reactivation and idiopathic facial paralysis have frequently been documented in connection with a few virus vaccinations, such as influenza and hepatitis B. It is thus not quite unexpected that patients of both conditions concerning SARS-CoV-2 vaccination have lately been publicized. Evidence of peripheral facial paralysis has even appeared from a phase III clinical trial with COVID-19 vaccines.

Nevertheless, no other documented cases of Ramsay-Hunt syndrome heeding COVID-19 vaccination or any other virus vaccination in the recent publications. This is presumably because herpes zoster accounts for shorter than 1% of all patients of herpes zoster and only 12% of peripheral facial paralysis cases, whose potential connections with vaccines are already infrequent. Thus, the COVID-19 is estimated to have very minimal imapct over the global market.

By Treatment Type

• Prescription Treatment

Antivirals

Painkillers

• NSAIDs
• Opioids

Steroids

• Supporting Treatment

Ophthalmic Solutions

By Route of Administration

• Oral
• Intravenous
• Other

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

UK

France

Italy

Spain

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In June 2023, GlaxoSmithKline (GSK) obtained the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for a renewed indication of its shingles (herpes zoster) vaccine, Shingrix, a recombinant zoster vaccine, adjuvanted [RZV)].
• In February 2023, Pfizer Inc. and BioNTech SE began a Phase I/II trial for the parties' mRNA vaccines for shingles (Herpes Zoster), for which there is no presently authorized vaccine. The multicenter, randomized, managed, dose-selection investigation intended to assess the safety, tolerability, and immunogenicity of mRNA vaccine nominees against shingles.

Competitive Landscape

The major global players in the market include GSK plc., BAUSCH HEALTH COMPANIES INC., Teva Pharmaceuticals USA, Inc., Pfizer Inc., Apotex Inc., Sandoz Canada Inc., Novartis Pharmaceuticals Corporation, and Cipla among others.

Why Purchase the Report?

• To visualize the Global Herpes Zoster Infection Treatment Market segmentation based on treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Herpes Zoster Infection Treatment Market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.

The Global Herpes Zoster Infection Treatment Market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies